Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Amen Clinics, Inc.New Study Links ADHD to More Than Fourfold Higher Hazard of Cognitive ImpairmentDr. Daniel Amen calls for greater attention to lifelong brain health following research involving more than 187,000 adults. — A new JAMA Psychiatry study of 187,341 adults aged 50 and older found that 6.7% of participants diagnosed with...
- HealthForce Kentucky to Share Its Immersive Health Science Model at NCHSE 20262026 zSpace Program of Distinction honoree will show how one AR/VR ecosystem powers mobile, K-12, and workforce development healthcare training
- Alvotech og Advanz Pharma fyrst til að sækja um markaðsleyfi fyrir hliðstæðu við augnlyfið Eylea í háum styrkREYKJAVÍK (14. október 2026) - Alvotech (NASDAQ: ALVO, ALVO SDB) og Advanz Pharma hafa lagt inn umsókn til Lyfjastofnunar Evrópu (EMA) um markaðsleyfi fyrir fyrirhugaða hliðstæðu við augnlyfið Eylea (aflibercept) í háum styrk, 8 mg. Þetta er í fyrsta sinn sem sótt er um markaðsleyfi einhverstaðar í heiminum fyrir hliðstæðu við Eylea í þessum styrkleika, samkvæmt opinberum upplýsingum.
- Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mgAVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
- SamsungSamsung Health Makes Sleep Coaching Easier To Start and Tailors Weekly GuidanceCompanies: Samsung ElectronicsSamsung Electronics today announced a major update to the Samsung Health app, making Sleep Coaching even easier to start by lowering the data requirement to begin. The update also delivers more personalized sleep guidance and expanded running program tiers to help users build lasting, healthier routines. Sleep Coaching Becomes Easier To Start and More Personalized […]
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific MarketsTokyo, Japan and Cambridge, UK, 14 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma Japan Co., Ltd. (“Nxera Pharma Japan”), has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for QUVIVIQ® (daridorexant), a treatment for insomnia, in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand (the “Territory”).
- GeneOnlineFrom Hospital AI to Home Monitoring: Taiwan's Health-Tech Sector Tests Its U.S. Market Fit in DallasTaiwan's healthcare technology sector has no shortage of devices, AI models or clinical data. The harder question is what happens when those technologies leave Taiwan: whether they can validate across different patient populations, clear U.S....
- Likang Life SciencesLikang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will...
- HIMS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --
- Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody ConjugateOrum announced that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC.
- Osara HealthOsara Health and Medibank partner to bring one-on-one cancer coaching to membersFrom 14 October, eligible Medibank members living with cancer can access Osara Health's Cancer Coach program for personalised support with the physical and emotional challenges of diagnosis and treatment. SYDNEY, Oct. 13, 2026 -- Osara Health has partnered with Medibank, one...